日本の局所進行膵がん市場：2025年～2033年

日本の局所進行膵がんの市場規模は、2024年に4,709万米ドルとなりました。同市場は、2033年には8,904万米ドルに達すると予測され、予測期間の2025年～2033年のCAGRは7.4%になると予測されています。

同市場における局所進行膵がん（LAPC）とは、腫瘍が膵臓とその周囲の局所構造にとどまって、肝臓、肺、遠隔リンパ節などの遠隔臓器には転移していない病期を指します。この段階では、がんは局所的に進展しており、上腸間膜動脈や門脈などの血管、十二指腸、胆管、脾臓などの臓器など、近傍の重要な構造物に浸潤している可能性があります。

日本では、LAPCは切除不能に分類されることが多く、これは腫瘍が重要な血管や神経を包んでいたり、近接しているために外科的切除が不可能であることを意味します。このような状況で手術を試みると重篤な合併症を引き起こす可能性があるため、手術以外の治療法が第一の標準治療となっています。

日本における現在の治療法は、化学療法（特にFOLFIRINOXまたはゲムシタビン＋ナブパクリタキセル）、放射線療法、標的療法（例えば、特定の遺伝子変化を有する患者に対するラロトレクチニブ、エントレクチニブ）、免疫療法（例えば、MSI-H/dMMR腫瘍に対するペムブロリズマブ）を組み合わせた多剤併用療法を重視しています。

プレシジョン・メディシンの進展、バイオマーカー主導型治療の採用拡大、政府の強力なヘルスケア支援により、日本のLAPC市場は着実な成長を遂げており、治療イノベーションと患者転帰改善の大きな機会を有しています。

標的療法と免疫療法の採用増加は、日本のLAPC市場における変革の促進要因であり、従来の化学療法を超えた治療パラダイムを再構築しています。日本は、C-CAT（がんゲノム先端治療研究センター）やSCRUM-Japan GI-SCREEN（世界最大級の全国規模のがんゲノムスクリーニング・プロジェクト）などの戦略的な政府イニシアティブに支えられ、個別化腫瘍学の最前線にいます。これらのプログラムにより、膵臓がん患者における実用的な変異やバイオマーカーの同定が容易になり、画一的な治療を超えたオーダーメイドの治療戦略が可能になります。

歴史的にFOLFIRINOXやゲムシタビン＋ナブパクリタキセルなどの化学療法レジメンに依存してきた日本の医療システムは、現在、強固なゲノム検査インフラと国のヘルスケア政策に支えられ、プレシジョン・メディシンを急速に統合しつつあります。BRCA変異腫瘍に対するPARP阻害剤（オラパリブなど）、NTRK融合陽性がんに対するTRK阻害剤（ラロトレクチニブ、エントレクチニブ）などの標的療法は、がんの特定の遺伝的促進因子を阻害する能力があるため、ますます利用されるようになっています。

同様に、MSI-H/dMMR腫瘍に対して承認されたペムブロリズマブのような免疫療法は、特にバイオマーカーが特定された患者において浸透しつつあります。コンパニオン診断薬が広く利用できるようになったことと、日本の保険制度による償還支援が相まって、これらの治療法は主要な医療機関で利用できるようになっています。

日本膵臓学会などの診療ガイドラインも、これらの治療を実践に取り入れ始めており、その普及を加速しています。全体として、分子標的治療や免疫学的治療へのシフトは、LAPC患者の予後を改善するだけでなく、日本の腫瘍学市場の革新と成長にも拍車をかけています。

日本の局所進行膵がん（LAPC）市場の成長と治療の成功に影響を及ぼす最も大きな障壁の一つは、効果的な早期発見ツールの不在による診断の遅れです。

この診断の遅れは、外科的介入の治療機会を制限するだけでなく、化学療法や放射線療法のような全身療法への依存度を高め、根治手術に比べて生存期間の延長効果が低いことが多いです。市場の観点からは、このような診断上のギャップは、新たな早期介入や新規治療の対象となる患者の潜在的なプールを著しく減少させます。また、進行期ではより集中的で長期にわたる治療が必要となるため、ヘルスケアシステムの経済的負担も増大します。

したがって、効果的な早期発見ツールの欠如とそれに伴う診断の遅れは、日本のLAPC分野における臨床転帰と市場成長の双方にとって重大な抑制要因となっています。改善されたバイオマーカー研究、AIを活用した画像診断、または国の検診プログラムを通じてこのギャップに対処すれば、日本の膵がん管理の状況を一変させる可能性があります。

当レポートでは、日本の局所進行膵がん市場について調査し、市場の概要とともに、治療別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界展望

• 市場のリーダーとパイオニア
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 日本の局所進行膵臓がん市場（治療別）

• 化学療法
• 手術
• 放射線治療
• 標的療法
• 免疫療法

第6章 日本の局所進行膵臓がん市場（エンドユーザー別）

• 病院
• 専門クリニック
• 研究機関

第7章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第8章 企業プロファイル

• Bristol-Myers Squibb Company
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• Pfizer Inc.
• Merck &Co., Inc.
• Fresenius Kabi AG
• Teva Pharmaceutical Industries Ltd
• F. Hoffmann-La Roche Ltd.
• Sun Pharmaceutical Industries Ltd.
• Merus NV
• CHEPLAPHARM Arzneimittel GmbH
• Bayer AG
• Eli Lilly and Company
• MITSUBISHI HEAVY INDUSTRIES, LTD.

第9章 仮定と調査手法

第10章 付録

The Japan locally advanced pancreatic cancer market reached US$ 47.09 million in 2024 and is expected to reach US$ 89.04 million by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Locally advanced pancreatic cancer (LAPC) in the market refers to a stage of the disease where the tumor remains confined to the pancreas and surrounding regional structures but has not metastasized to distant organs such as the liver, lungs, or remote lymph nodes. At this stage, the cancer has extended locally and may involve critical nearby structures, including blood vessels like the superior mesenteric artery or portal vein, and organs such as the duodenum, bile ducts, and spleen.

In Japan, LAPC is often classified as unresectable, meaning surgical removal is not feasible due to the tumor's encasement of or proximity to vital blood vessels and nerves. Attempting surgery under these conditions may result in severe complications, which makes non-surgical treatment modalities the primary standard of care.

The current treatment landscape in Japan emphasizes a multimodal approach, combining Chemotherapy (notably FOLFIRINOX or gemcitabine plus nab-paclitaxel), radiation therapy, targeted therapy (e.g., larotrectinib, entrectinib for patients with specific genetic alterations), and immunotherapy (e.g., pembrolizumab for MSI-H/dMMR tumors).

With advancements in precision medicine, growing adoption of biomarker-driven therapies, and strong government healthcare support, the Japanese LAPC market is witnessing steady growth and holds significant opportunities for therapeutic innovation and patient outcome improvement.

Market Dynamics: Drivers & Restraints

Adoption of Targeted and Immunotherapies

The increasing adoption of targeted therapies and immunotherapies represents a transformative driver in the Japan LAPC market, reshaping the treatment paradigm beyond traditional chemotherapy. Japan has been at the forefront of personalized oncology, supported by strategic governmental initiatives such as C-CAT (Center for Cancer Genomics and Advanced Therapeutics) and SCRUM-Japan GI-SCREEN, one of the largest nationwide cancer genomic screening projects globally. These programs facilitate the identification of actionable mutations and biomarkers in pancreatic cancer patients, allowing for tailored therapeutic strategies that go beyond one-size-fits-all treatments.

Historically reliant on chemotherapy regimens like FOLFIRINOX and gemcitabine with nab-paclitaxel, the Japanese healthcare system is now rapidly integrating precision medicine, supported by robust genomic testing infrastructure and national healthcare policies. Targeted therapies, such as PARP inhibitors (e.g., olaparib) for BRCA-mutated tumors and TRK inhibitors (larotrectinib, entrectinib) for NTRK fusion-positive cancers, are being increasingly utilized due to their ability to interfere with specific genetic drivers of cancer.

Similarly, immunotherapies like pembrolizumab, approved for MSI-H/dMMR tumors, are gaining ground, particularly in patients with defined biomarkers. The widespread availability of companion diagnostics, coupled with reimbursement support from Japan's national insurance system, has made these therapies accessible across major institutions.

Clinical guidelines from bodies such as the Japan Pancreas Society have also begun incorporating these treatments into practice, accelerating their adoption. Overall, this shift toward molecularly targeted and immunologically driven therapies is not only improving the prognosis for LAPC patients but is also fueling innovation and growth in Japan's oncology market.

Delayed Diagnosis and Limited Early Detection Tools

One of the most significant barriers impacting the growth and treatment success in the Japan locally advanced pancreatic cancer (LAPC) market is the delayed diagnosis caused by the absence of effective early detection tools.

This delay in diagnosis not only limits the therapeutic window for surgical intervention but also places a heavier reliance on systemic therapies like chemotherapy or radiation, which are often less effective in prolonging survival compared to curative surgery. From a market perspective, this diagnostic gap significantly reduces the potential pool of patients eligible for emerging early-stage interventions and novel therapies. It also increases the economic burden on the healthcare system due to the need for more intensive, prolonged treatments in advanced stages.

Therefore, the lack of effective early detection tools and the consequent delayed diagnosis act as a critical restraint on both clinical outcomes and market growth in Japan's LAPC segment. Addressing this gap through improved biomarker research, AI-enhanced imaging diagnostics, or national screening programs could potentially transform the landscape of pancreatic cancer management in the country.

Segment Analysis

The Japan locally advanced pancreatic cancer market is segmented based on therapy and end-user.

Therapy:

The chemotherapy segment in the therapy is expected to dominate the Japan locally advanced pancreatic cancer market share

Chemotherapy remains the cornerstone of treatment for locally advanced pancreatic cancer (LAPC) in Japan. It works by targeting and killing rapidly dividing cells, including cancerous ones, thereby inhibiting tumor progression. Chemotherapy can be administered as monotherapy or in combination regimens, depending on the patient's performance status and clinical profile.

In Japan, the most commonly used chemotherapy agents for LAPC include Gemcitabine, FOLFIRINOX, Nab-Paclitaxel, Cisplatin, nd Others under clinical evaluation or in combination therapies. The Japan Pancreas Society (JPS) Practice Guidelines 2022 endorse FOLFIRINOX, Gemcitabine + nab-paclitaxel, and Gemcitabine monotherapy as the primary chemotherapy options for managing LAPC.

Japan's structured adherence to evidence-based treatment pathways and its high healthcare infrastructure standard have positioned chemotherapy as a critical pillar in the LAPC market. Its relatively widespread accessibility, strong clinical efficacy, and potential to convert unresectable tumors into operable cases make it a dominant therapeutic strategy.

As ongoing trials investigate newer agents and optimized combinations, chemotherapy is expected to retain its primary role in managing LAPC while evolving in precision and patient personalization.

Competitive Landscape

The major players in the Japan locally advanced pancreatic cancer market include Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Merus N.V., CHEPLAPHARM Arzneimittel GmbH, Bayer AG, Eli Lilly and Company, MITSUBISHI HEAVY INDUSTRIES, LTD. and among others.

Key Developments

• In December 2024, Zai Lab Limited and Novocure announced positive results from the Phase 3 PANOVA-3 trial, which achieved its primary endpoint by demonstrating a statistically significant improvement in median overall survival (mOS) compared to the control group. The PANOVA-3 studies evaluated the effectiveness of Tumor Treating Fields (TTFields) therapy used in combination with gemcitabine and nab-paclitaxel as a first-line treatment for patients with unresectable, locally advanced pancreatic adenocarcinoma.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan locally advanced pancreatic cancer market report delivers a detailed analysis with 42 key tables, more than 25 visually impactful figures, and 136 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Therapy
• 2.4. Snippet by End-User

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Adoption of Targeted and Immunotherapies
    • 3.1.1.2. Rising Incidence of Pancreatic Cancer in an Aging Population
  • 3.1.2. Restraints
    • 3.1.2.1. Delayed Diagnosis and Limited Early Detection Tools
    • 3.1.2.2. Severe Side Effects of Chemotherapy
  • 3.1.3. Opportunity
    • 3.1.3.1. Advancements in Precision Medicine
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Japan Locally Advanced Pancreatic Cancer Market, By Therapy

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy
  • 5.1.2. Market Attractiveness Index, By Therapy
• 5.2. Chemotherapy*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Folfirinox
  • 5.2.4. Gemcitabine
  • 5.2.5. Nab-Paclitaxel
  • 5.2.6. Cisplatin
  • 5.2.7. Others
• 5.3. Surgery
  • 5.3.1. Whipple Procedure
  • 5.3.2. Distal Pancreatectomy
  • 5.3.3. Total Pancreatectomy
• 5.4. Radiation Therapy
• 5.5. Targeted Therapy
  • 5.5.1. Larotrectinib
  • 5.5.2. Entrectinib
• 5.6. Immunotherapy

6. Japan Locally Advanced Pancreatic Cancer Market, By End-User

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 6.1.2. Market Attractiveness Index, By End-User
• 6.2. Hospitals*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Specialty Clinics
• 6.4. Research Institutions

7. Competitive Landscape and Market Positioning

• 7.1. Competitive Overview and Key Market Players
• 7.2. Market Share Analysis and Positioning Matrix
• 7.3. Strategic Partnerships, Mergers & Acquisitions
• 7.4. Key Developments in Product Portfolios and Innovations
• 7.5. Company Benchmarking

8. Company Profiles

• 8.1. Bristol-Myers Squibb Company
  • 8.1.1. Company Overview
  • 8.1.2. Product Portfolio
    • 8.1.2.1. Product Description
    • 8.1.2.2. Product Key Performance Indicators (KPIs)
    • 8.1.2.3. Historic and Forecasted Product Sales
    • 8.1.2.4. Product Sales Volume
  • 8.1.3. Financial Overview
    • 8.1.3.1. Company Revenue's
    • 8.1.3.2. Geographical Revenue Shares
    • 8.1.3.3. Revenue Forecasts
  • 8.1.4. Key Developments
    • 8.1.4.1. Mergers & Acquisitions
    • 8.1.4.2. Key Product Development Activities
    • 8.1.4.3. Regulatory Approvals, etc.
  • 8.1.5. SWOT Analysis
• 8.2. Pfizer Inc.
• 8.3. Merck & Co., Inc.
• 8.4. Fresenius Kabi AG
• 8.5. Teva Pharmaceutical Industries Ltd
• 8.6. F. Hoffmann-La Roche Ltd.*
• 8.7. Sun Pharmaceutical Industries Ltd.
• 8.8. Merus N.V.
• 8.9. CHEPLAPHARM Arzneimittel GmbH
• 8.10. Bayer AG
• 8.11. Eli Lilly and Company
• 8.12. MITSUBISHI HEAVY INDUSTRIES, LTD.

LIST NOT EXHAUSTIVE

9. Assumptions and Research Methodology

• 9.1. Data Collection Methods
• 9.2. Data Triangulation
• 9.3. Forecasting Techniques
• 9.4. Data Verification and Validation

10. Appendix

• 10.1. About Us and Services
• 10.2. Contact Us